MIRA Pharmaceuticals, Inc. (MIRA) est une société cotée en bourse dans le Santé secteur, opérant dans le Drug Manufacturers - General secteur d'activité. Le siège social de l'entreprise est situé à Baltimore, MD, United States. Le PDG actuel est Erez Aminov.
MIRA a date d'introduction en bourse 2023-08-14, 2 employés à temps plein, cotée sur le NASDAQ Capital Marke, une capitalisation boursière de $44.12M.
MIRA Pharmaceuticals, Inc. operates as a clinical development stage biopharmaceutical company. The company focuses on the development and commercialization of a new molecular synthetic tetrahydrocannabinol (THC) analog under investigation for the treatment of adult patients with anxiety and cognitive decline typically associated with early-stage dementia. It is developing MIRA1a, a synthetic cannabinoid analog to treat anxiety and chronic pain by targeting the cannabinoid type 1 and type 2 receptors. The company was formerly known as MIRA1a Therapeutics, Inc. MIRA Pharmaceuticals, Inc. was incorporated in 2020 and is headquartered in Baltimore, Maryland.
